Quadrant sees CME potential in Jobson titles

Share this article:
Quadrant HealthCom plans to beef up its med ed offering through four titles recently acquired from Jobson. “The idea is to integrate them into Quadrant and try to give them the kind of support they need to realize their potential,” said Steve Stoneburn, president and CEO of Quadrant. “We’re optimistic we can continue to grow that business.” The acquisitions broaden Quadrant’s audience to 500,000 readers across 13 titles, bolstering the firm’s primary care portfolio and giving it entrée into the neurology, psychiatry pulmonary and NP/PA specialty categories. The titles include Clinician Reviews, Neurology Reviews, Neuropsychiatry Reviews and Pulmonary Reviews. A fifth title included in the deal, Women’s Health in Primary Care, will cease publication, with elements to be added to Quadrant’s The Female Patient. Editor-in-chief Maura Griffith will serve as chief of content development activities at Quadrant Medical Education. Roland DeSilva of DeSilva + Phillips, which brokered the deal for Quadrant, called it “an excellent strategic fit for Quadrant. It rounds out their ability to service the healthcare industry.” Terms of the deal were not disclosed, but revenues for the titles are understood to exceed $10 million.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.